Using hypothetical scenarios relating to a Gleason Group 1 prostate cancer, the authors tested different possible labels to describe pathology findings (‘adenocarcinoma’ vs ‘acinar neoplasm’ vs ‘prostatic acinar neoplasm of low malignant potential’ vs ‘prostatic acinar neoplasm of uncertain malignant potential’ (‘PAN-LMP’)), and the disease in general (‘cancer’ vs ‘neoplasm’ vs ‘tumour’ vs ‘growth’). This evidence concerns the gene PDLIM7 and cancer.